Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6

NCT01488318 is registered in ClinicalTrials.gov with Julie E. Bauman, MD, MPH as lead sponsor.

NCT NCT01488318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6
Lead sponsor
Julie E. Bauman, MD, MPH
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2011
Completion date
August 31, 2016
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck